


## Analysis of Naproxen

(Under the Condition of draft for USP PF51(4), Naproxen Compounded Oral Suspension, ASSAY)



### Conditions

**System** : Primaide (HITACHI)  
**Guard Column** : Inertsil ODS-EP (GL Sciences Inc.)  
 (5  $\mu$ m, 20 x 3.9 mm I.D.)  
**Column Cat. No.** : 5020-90916  
**Column** : Inertsil ODS-EP (GL Sciences Inc.)  
 (5  $\mu$ m, 100 x 4.6 mm I.D.)  
**Column Cat. No.** : 5020-02644  
**Eluent** : CH<sub>3</sub>OH/Buffer\*=82/18, v/v  
**Flow Rate** :

Time (min)	Flow Rate (mL/min)
0.0	0.8
1.0	0.85
2.0	0.9
3.0	1.0

### Analyte:

1. Ranitidine hydrochloride 1.0 mg/mL  
 2. Naproxen 0.025 mg/mL

### RSD of

the peak area of 1 (%) (n=6) : 0.41 ( $\leq$ 2.0%)  
 the peak area of 2 (%) (n=6) : 0.16 ( $\leq$ 2.0%)

**Col. Temp.** : 40  $^{\circ}$ C  
**Detection** : UV 232 nm (Primaide 1435 DAD)  
**Injection Vol.** : 20  $\mu$ L  
**Sample** : Standard in CH<sub>3</sub>OH

\*: 5 mM solution of ammonium formate. Adjust with formic acid to a pH of 4.